Chemical structure of Tofacitinib.
Western blot analysis of extracts from NK-92 cells, serum-starved overnight and untreated (-) or treated with Human Interleukin-2 (hIL-2) #8907 (10 ng/ml, 15 min; +), either with or without Tofacitinib pretreatment (1 hr) at the indicated concentrations, using Phospho-Jak3 (Tyr980/981) (D44E3) Rabbit mAb #5031, Jak3 (D1H3) Rabbit mAb #8827, Phospho-Stat3 (Tyr705) (D3A7) XP® Rabbit mAb #9145, Stat3 (79D7) Rabbit mAb #4904, and β-Actin (D6A8) Rabbit mAb #8457.
Tofacitinib is supplied as a lyophilized powder. For a 50 mM stock, reconstitute the 10 mg of powder in 640.27 of μl DMSO. Working concentrations and length of treatment can vary depending on the desired effect, but it is typically used at 5-500 nM for 1-72 hr.
Solubility: Soluble in DMSO and ethanol at 100 mg/ml. Very poorly soluble in water.
Store lyophilized or in solution at -20ºC, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.
|Molecular Weight||312.37 g/mol|
|Solubility||Soluble in DMSO and EtOH at 100mg/ml.|
Tofacitinib is a cell permeable Janus kinase (JAK) inhibitor with demonstrated preference to inhibiting JAK1 and JAK3 (1). Tofacitinib inhibits JAK isoforms 1, 2, and 3 with IC50 values of 6.1, 12, and 8.0 nM, respectively; the reported IC50 value relative to Tyk2 is 176 nM (2). Research studies show that tofacitinib primarily blocks γc cytokine receptors and inhibits cytokine production, which suggests that tofacitinib blocks cytokine action during both innate and adaptive responses (1,3). The overall effect of tofacitinib is to reduce inflammatory responses through selective inhibition of JAK family members (4).
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST's products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST's Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.